News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Prudential Financial rated buy at $107 with a $120 target, citing near-5% yield and buyback and dividend optionality.
  • Senate Agriculture chair and former officials warn U.S. crop growers face severe financial strain.
  • $12 billion government aid to producers arrives this month but will cover only part of sector losses.
  • NIESR forecasts UK unemployment will average 5.4% this year, the highest since 2015.
  • NIESR says rising labour costs are a key driver of higher unemployment.
  • NIESR raises near-term growth forecasts.
  • NIESR expects two Bank of England rate cuts this year.

Latest Articles

JPMorgan Stays Neutral on Sarepta After Three-Year EMBARK Readout; Questions Remain on Commercial Trajectory

JPMorgan Stays Neutral on Sarepta After Three-Year EMBARK Readout; Questions Remain on Commercial Trajectory

JPMorgan has kept a Neutral rating and an $18.00 price target on Sarepta Therapeutics following the company’s release of topline three-year Phase 3 EMBARK results for Elevidys in ambulatory Duchenne muscular dystrophy (DMD) patients. The data report statistically significant and sustained improvements in key motor endpoints versus a pre-specified p…

Canaccord Sees Upside in Acadia Pharmaceuticals, Reaffirms $32 Target

Canaccord Sees Upside in Acadia Pharmaceuticals, Reaffirms $32 Target

Canaccord Genuity has reiterated a Buy rating and set a $32.00 price target on Acadia Pharmaceuticals (ACAD), arguing the shares are undervalued when judged on current approved products alone. Trading near $26.86, the stock aligns with consensus Buy recommendations and appears undervalued by InvestingPro Fair Value metrics. Canaccord also highlight…

Evercore Stands Pat on UPS After Q4 Beat; Revenue Up, Margin Guidance Lags

Evercore Stands Pat on UPS After Q4 Beat; Revenue Up, Margin Guidance Lags

Evercore ISI maintained an In Line rating and a $113.00 price target for UPS after the company's fourth-quarter 2025 results showed earnings and revenue ahead of consensus. The delivery giant reported adjusted EPS of $2.38 and consolidated revenue of $24.479 billion, while issuing full-year 2026 revenue and margin guidance that left some analysts c…

South Sudan urges opposition to halt as rebel advance fuels displacement in Jonglei

South Sudan urges opposition to halt as rebel advance fuels displacement in Jonglei

South Sudan's government has called on opposition forces to stop fighting after a rebel advance and continued clashes in Jonglei state displaced hundreds of thousands and raised fears of a return to large-scale civil conflict. The United Nations says the fighting is at a level not seen since 2017, while the government says its forces have repelled …

Tadawul Climbs as Construction and Real Estate Names Lead Gains

Tadawul Climbs as Construction and Real Estate Names Lead Gains

Saudi Arabia's equity market closed higher on Tuesday, with the Tadawul All Share index rising 0.99% to reach a new one-month high. Strength in Building & Construction, Real Estate Development and Industrial Investment stocks supported the advance, while mining, paper manufacturing and cement names posted the day’s largest declines. Commodity and c…

Helix Acquisition Corp. III Completes $172.5 Million IPO, Lists on Nasdaq

Helix Acquisition Corp. III Completes $172.5 Million IPO, Lists on Nasdaq

Helix Acquisition Corp. III completed its initial public offering at $10 per share, selling 17.25 million Class A ordinary shares and raising $172.5 million. The offering included the full exercise of the underwriters' over-allotment option and was accompanied by a private placement to the company's sponsor. The company, formed as a special purpose…

Scotiabank Starts Coverage of CGI With Sector Perform, C$140 Target

Scotiabank Starts Coverage of CGI With Sector Perform, C$140 Target

Scotiabank has initiated coverage of CGI Group Inc with a Sector Perform rating and a C$140.00 price objective. The bank cites the company’s exposure to discretionary IT spending in its Consulting business as the primary reason for a neutral stance, while noting valuation metrics that sit modestly above peer averages. CGI has also announced a globa…

JPMorgan Sticks With Overweight on Vera Therapeutics, Sees Near-Term Upside as FDA Moves Atacicept Forward

JPMorgan Sticks With Overweight on Vera Therapeutics, Sees Near-Term Upside as FDA Moves Atacicept Forward

JPMorgan reiterated its Overweight rating and $96.00 price target on Vera Therapeutics (NASDAQ: VERA), signaling substantial upside from the stock's current trading level. The firm highlighted atacicept, Vera's lead candidate for immunoglobulin A nephropathy (IgAN), as well positioned in the B-Cell modulator space. The outlook is reinforced by an F…

JPMorgan Delta One Desk Flags Shift From U.S. to International Equity ETFs

JPMorgan Delta One Desk Flags Shift From U.S. to International Equity ETFs

JPMorgan’s Delta One Desk reports a marked rotation away from U.S. equity ETFs last week, with significant inflows into international developed and emerging market ETFs. Sector-level moves favored Materials, Energy, Financials and Healthcare, while Utilities and Consumer sectors saw outflows. Fixed income ETFs recorded above-average inflows led by …

IonQ to Buy SkyWater Technology for $1.8 Billion in Cash-and-Stock Deal

IonQ to Buy SkyWater Technology for $1.8 Billion in Cash-and-Stock Deal

IonQ, Inc. has agreed to acquire SkyWater Technology in a deal that values the foundry supplier at $1.8 billion in equity. The transaction, structured as $15 in cash plus $20 in IonQ stock per SkyWater share for a total of $35 per share, is expected to close in the second or third quarter of 2026 pending shareholder and regulatory approvals. The pu…